Page last updated: 2024-10-29

indirubin-3'-monoxime and Leukemia, Myeloid

indirubin-3'-monoxime has been researched along with Leukemia, Myeloid in 2 studies

indirubin-3'-monoxime: has antiangiogenic activity
indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.

Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Song, JH1
Lee, JE1
Cho, KM1
Park, SH1
Kim, HJ1
Kim, YC1
Kim, TS1
Zhen, Y1
Sørensen, V1
Jin, Y1
Suo, Z1
Wiedłocha, A1

Other Studies

2 other studies available for indirubin-3'-monoxime and Leukemia, Myeloid

ArticleYear
5-diphenylacetamido-indirubin-3'-oxime as a novel mitochondria-targeting agent with anti-leukemic activities.
    Molecular carcinogenesis, 2016, Volume: 55, Issue:5

    Topics: Antineoplastic Agents; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistanc

2016
Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK.
    Oncogene, 2007, Sep-27, Volume: 26, Issue:44

    Topics: Animals; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 2; Endocytosis; ErbB Receptors; Fib

2007